Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination

Published:2021-10-28 Issue:12 Volume:10 Page:1419-1431
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Mahar Kelly M.¹,Caltabiano Stephen²,Andrews Susan³,Ramanjineyulu Bandi⁴,Chen Liangfu⁵,Young Graeme⁶,Pereira Adrian⁶,Lindsay Alistair C.²,van den Berg Frans⁷,Cobitz Alexander R.²

Affiliation:

1. Clinical Pharmacology Modeling & Simulation GlaxoSmithKline Collegeville Pennsylvania USA

2. Development‐Clinical Sciences GlaxoSmithKline Collegeville Pennsylvania USA

3. Clinical Science & Study Operations GlaxoSmithKline Research Triangle Park North Carolina USA

4. Clinical Statistics GlaxoSmithKline Bangalore India

5. Drug Metabolism and Pharmacokinetics GlaxoSmithKline Collegeville Pennsylvania USA

6. Disposition & Biotransformation GlaxoSmithKline Ware UK

7. Hammersmith Medicines Research London UK

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1029

Reference27 articles.

1. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

2. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease

3. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

4. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD

5. Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string;Pharmacology Research & Perspectives;2023-10-26

2. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis;Journal of Pharmaceutical and Biomedical Analysis;2023-10

3. Daprodustat;Hospital Pharmacy;2023-05-17

4. Comparison of Two Manufacturing Processes of Daprodustat for Bioequivalence and Dissolution in Healthy Volunteers: A Randomized Crossover Study;Clinical Pharmacology in Drug Development;2023-05

5. Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function;Clinical Pharmacology in Drug Development;2022-03-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3